Two trials have shown the safety and efficacy of MSE for antegrade and total enteroscopy respectively [1,2]. The use of MSE in real-life settings outside MSE-expert centres and safety and effectiveness of MSE in post-surgical patients and patients with altered anatomy had not yet been investigated. The SAMISEN trial (NCT03955081) enrolled 10 European centres with a variety of MSE experience [3]. For the core analysis, 251 patients were included, and 47 patients were allocated to the training phase for novel MSE users. Primary endpoint was a non-inferior safety profile of the procedure, defined as a serious adverse event (SAE) rate <8%. Dr Torsten Beyna (Evangelic Hospital Düsseldorf, Germany) presented the results.
MSE demonstrated favourable safety outcomes. The overall SAE rate was 2.3% (95% CI 0.9-4.8). The core phase had an SAE rate of 2.0% and the training phase had an SAE rate of 4.3%. The SAEs included a perforation and a deep mucosal laceration of the oesophagus. Subgroup analysis showed that within the postsurgical/altered anatomy subgroup the SAE rate was 1.9%, representing only 1 case out of 53 participants. In 9.6% of the patients AEs occurred, mostly related to clinically asymptomatic mucosal lacerations at the level of the oesophagus, the cardia, and the small bowel. The anatomic region of interest was reached in 88% of the performed procedures, total enteroscopy was successful in >50% of the patients that were planned for this procedure (n=81). The diagnostic yield of MSE was 83% and the therapeutic yield was 60.2% in this study.
- Beyna T, et al. Gut. 2021; 70(2):261-267
- Beyna T, et al. Gastrointest Endosc. 2021;93(6):1362-1370
- Beyna T, et al. Motorized spiral enteroscopy: results on an international multicenter, prospective clinical trial (samisen) including patients with postsurgical/altered anatomy. LB03, UEG Week 2021 Virtual Congress, 03–05 October.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Novel tool can reliably exclude submucosal invasion in colorectal polyps Next Article
Serious adverse events put a stop to ASTIClite trial for CD »
« Novel tool can reliably exclude submucosal invasion in colorectal polyps Next Article
Serious adverse events put a stop to ASTIClite trial for CD »
Table of Contents: UEGW 2021
Featured articles
Updates in Biologics
Risankizumab meets primary endpoints in maintenance study for CD patients
Ustekinumab treat-to-target strategy offers long-term alternative for standard-of-care in CD
Long-term efficacy data of dupilumab for eosinophilic oesophagitis
Updates in Small Molecules
Upadacitinib efficacious and safe as maintenance therapy for UC
Upadacitinib outperforms placebo in UC patients with inadequate response to biologics
Rapid symptom control for UC patients on upadacitinib
Filgotinib demonstrates promising results for various lines of therapy in UC
Filgotinib demonstrates long-term corticosteroid-sparing effects in UC
Long-term benefits of tofacitinib for substantial proportion of UC patients
Ritlecitinib and brepocitinib are promising JAK inhibitors for UC
First pharmacological therapy with clear efficacy in coeliac disease patients
Endoscopy
Motorised spiral enteroscopy safe in real-life and in patients with altered anatomy
Novel tool can reliably exclude submucosal invasion in colorectal polyps
Other Updates
Serologic response to COVID-19 mRNA vaccine reduced in IBD patients on anti-TNFα
Serious adverse events put a stop to ASTIClite trial for CD
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy